uniQure (NASDAQ:QURE) Rating Increased to Strong-Buy at Raymond James

Raymond James upgraded shares of uniQure (NASDAQ:QURE) from an outperform rating to a strong-buy rating in a research report report published on Tuesday, Marketbeat Ratings reports. The firm currently has $52.00 price target on the biotechnology company’s stock, up from their prior price target of $20.00.

QURE has been the subject of a number of other research reports. StockNews.com upgraded uniQure to a “sell” rating in a report on Thursday, October 17th. Cantor Fitzgerald raised their price objective on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of uniQure in a report on Wednesday, November 6th. The Goldman Sachs Group lowered their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada reduced their price target on uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.33.

uniQure Stock Performance

NASDAQ:QURE opened at $15.30 on Tuesday. The business has a 50 day moving average price of $6.42 and a 200-day moving average price of $6.15. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $17.39. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The firm has a market cap of $745.72 million, a PE ratio of -3.08 and a beta of 0.89.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. Equities research analysts predict that uniQure will post -3.74 earnings per share for the current year.

Insider Transactions at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

Institutional investors have recently modified their holdings of the stock. RTW Investments LP purchased a new position in shares of uniQure in the 3rd quarter worth about $49,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,663 shares in the last quarter. Atria Investments Inc purchased a new stake in shares of uniQure during the third quarter valued at approximately $53,000. Quarry LP bought a new stake in shares of uniQure during the third quarter valued at approximately $58,000. Finally, Vanguard Personalized Indexing Management LLC increased its position in shares of uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,306 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.